GSK statement on avodart™ (dutasteride) for prostate cancer risk reduction

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)530
Number of pages1
JournalJournal of Urology
Volume186
Issue number2
DOIs
StatePublished - Aug 2011
Externally publishedYes

Fingerprint

Risk Reduction Behavior
Prostatic Neoplasms
Dutasteride

ASJC Scopus subject areas

  • Urology

Cite this

GSK statement on avodart™ (dutasteride) for prostate cancer risk reduction. / Walsh, Patrick.

In: Journal of Urology, Vol. 186, No. 2, 08.2011, p. 530.

Research output: Contribution to journalArticle

@article{e64798eaad604881937a15287bf3d811,
title = "GSK statement on avodart™ (dutasteride) for prostate cancer risk reduction",
author = "Patrick Walsh",
year = "2011",
month = "8",
doi = "10.1016/j.juro.2011.04.053",
language = "English (US)",
volume = "186",
pages = "530",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - GSK statement on avodart™ (dutasteride) for prostate cancer risk reduction

AU - Walsh, Patrick

PY - 2011/8

Y1 - 2011/8

UR - http://www.scopus.com/inward/record.url?scp=79960160704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960160704&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2011.04.053

DO - 10.1016/j.juro.2011.04.053

M3 - Article

VL - 186

SP - 530

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -